Abstract
Refractory Chronic Cough (RCC) imposes a significant burden on patients’ quality of life (QoL). Tools such as the Leicester Cough Questionnaire (LCQ) are used to assess this impact of cough. We report the burden at baseline in RCC populations enrolled in a study of the P2X3 antagonist BLU-5937.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
